Beijing Konruns Pharmaceutical Co Ltd
SSE:603590
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
Beijing Konruns Pharmaceutical Co Ltd
SSE:603590
|
6.7B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
993.5B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
292.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.2B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
244.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
307.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.9B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.1B USD |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Beijing Konruns Pharmaceutical Co Ltd
Glance View
Beijing Konruns Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of new drugs, with a focus on new special drugs. The company is headquartered in Beijing, Beijing and currently employs 473 full-time employees. The company went IPO on 2018-08-27. The firm's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Company’s present products under research include a range of innovative and generic drugs for tumors and blood. The firm mainly distributes its products in the domestic market.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Beijing Konruns Pharmaceutical Co Ltd is 6.6%, which is below its 3-year median of 11.1%.
Over the last 3 years, Beijing Konruns Pharmaceutical Co Ltd’s Net Margin has decreased from 14.3% to 6.6%. During this period, it reached a low of 5.1% on Dec 31, 2024 and a high of 17.4% on Mar 31, 2024.
